[Influenza vaccine split virion, inactivated]


Trade name: Flu-M [Influenza vaccine split virion, inactivated]. 

Generic name: Influenza vaccine [inactivated]. 

Pharmaceutical form: solution for intramuscular injection. 

Composition. One ampoule (1 dose of 0.5 mL) contains the following inactivated split influenza viruses cultivated on chick embryos which are represented by strains equal to the following strains: 

A/Guangdong-Maonan/SWL1536/2019 (H1N1) pdm09-like strain 

(A/Guangdong-Maonan/SWL1536/2019, CNIC-1909) 

15 μg of hemagglutinin 

A/Hong Kong/2671/2019 (H3N2)-like strain 

(A/Hong Kong/2671/2019, IVR-208) 

15 μg of hemagglutinin

B/Washington/02/2019-like strain 

(B/Washington/02/2019, wild type) 

15 μg of hemagglutinin

Excipients: Triton X-100, sodium chloride, disodium phosphate dodecahydrate, potassium dihydrogen phosphate, water for injections.

Description. Colourless slightly opalescent liquid. 

The vaccine strain composition is updated in accordance with WHO recommendations for the current epidemic season. 

Immunobiological properties. The vaccine induces specific immunity against relevant influenza type A and B strains. The immunity develops within 3 weeks after vaccination and lasts for 12 months. 

Pharmacotherapeutic group. MIBP – vaccine. 

АТС code: J07BB02. 

Indications. Active annual preventive immunization against seasonal influenza in people aged from 18 to 60 years. 

Vaccination is carried out annually in the autumn-winter period. Vaccination is possible at the beginning of an epidemic rise in the influenza incidence. 

The use of this vaccine should be based on official recommendations.


Allergic reactions to chicken protein and vaccine components. 

Allergic reactions to previously administered influenza vaccines. 

A strong reaction (temperature above 40 °С, oedema and hyperaemia over 8 cm in diameters at the injection site) or complications caused by previous administration of the drug. 

Acute infectious or non-infectious diseases, exacerbation of chronic diseases (the vaccination should be carried out after recovery or in the period of remission. 

In case of non-severe acute upper respiratory infections or acute intestinal illnesses, vaccination is performed after the body temperature has returned to normal. 

Use during pregnancy and lactation. No information available. Clinical studies have not been conducted.



Based on the clinical use of triple vaccine, it is recommended to carry out annual revaccination with influenza vaccine in view of the duration of vaccine-induced immunity caused and due to possible change of circulating influenza virus strains every year. One dose of 0.5 mL.

Target patient groups

Children: Not available

Geriatric patients: Not available

People with renal impairment: This product contains less than 1 mmol (39 mg) of potassium and less than 1 mmol (23 mg) of sodium per dose (0.1 mL), i.e. it basically does not contain potassium and sodium.


Vaccines and medicines